# US 2021/0063406 A1 · Ca ix - nir dyes and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0063406 A1
- Document ID: US20210063406A1
- Status: Published application
- Kind: A1
- Application number: 17/025,711
- Filed: 2020-09-18
- Published: 2021-03-04
- Earliest claimed: 2016-03-16
- Assignees: On Target Laboratories, LLC
- Applicants: On Target Laboratories, Inc.
- Inventors: Sumith A. Kularatne; Mini Thomas
- Web page: https://patentgrep.com/patent/US20210063406A1

## CPC

- A61B 1/000094: {extracting biological structures}
- A61B 1/00009: {of image signals during a use of endoscope}
- A61B 1/043: {for fluorescence imaging}
- A61B 5/0071: {by measuring fluorescence emission}
- A61B 5/0073: {by tomography, i.e. reconstruction of 3D images from 2D projections (A61B5/0066 takes precedence)}
- A61B 5/0084: {for introduction into the body, e.g. by catheters (A61B5/1459 takes precedence)}
- A61B 5/7282: {Event detection, e.g. detecting unique waveforms indicative of a medical condition (cough events A61B5/0823; seizures A61B5/4094; sleep apnoea A61B5/4818)}
- A61K 49/0052: {Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)}
- C07D 209/12: Radicals substituted by oxygen atoms
- C07D 311/90: with hydrocarbon radicals, substituted by amino radicals, directly attached in position 9
- C09B 23/0008: {substituted on the polymethine chain}
- C09B 23/0025: {the substituent being bound through an oxygen atom}
- C09B 23/0066: {the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid)}
- C09B 23/166: {containing two or more nitrogen atoms (hydrazon dyes -CH=N-N- C09B26/02)}
- C12Y 402/01001: Carbonate dehydratase (4.2.1.1), i.e. carbonic anhydrase
- G01N 33/573: for enzymes or isoenzymes
- G01N 33/575: for cancer
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 33/582: {with fluorescent label}
- G01N 33/583: {with non-fluorescent dye label}
- A61B 90/20: Surgical microscopes characterised by non-optical aspects
- A61B 90/30: Devices for illuminating a surgical field, the devices having an interrelation with other surgical devices or with a surgical procedure
- A61B 2090/304: {using chemi-luminescent materials}
- A61B 2090/373: {using light, e.g. by using optical scanners}
- A61B 2090/502: {Headgear, e.g. helmet, spectacles}
- A61B 2560/0431: Portable apparatus, e.g. comprising a handle or case
- A61K 49/0017: {Fluorescence in vivo}
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- G01N 2333/988: Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C09B: ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES {, e.g. PIGMENTS}; MORDANTS; LAKES (fermentation or enzyme using processes to synthesise a desired chemical compound C12P)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a ligand that binds to the active site of carbonic anhydrase, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid, amide, ureido, or polyethylene glycol derivative thereof. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.

## Claims

### Claim 1

A method of diagnostic imaging of diseased tissue, wherein the diseased tissue comprises at least one CA IX-expressing cell, comprising the step of administering to a subject an effective amount of a compound, pharmaceutically acceptable salt of the compound, or a composition comprising the compound, wherein the compound has the formula:
B-W-X-Y-Z
wherein B is a CA IX-targeted molecule is selected from the group consisting of
wherein n is 0, 1, 2, 3, . . . ; m is 0, 1, 2, 3, 4, 5, . . . and p is 0, 1, 2, 3, . . . ;
W is an extended hydrophobic residue;
X is a hydrophobic spacer;
Y is an amino acid spacer; and
Z is a NIR dye.

### Claim 2 (depends on 1)

The method of claim 1, wherein W is selected from the group consisting of a hydrophobic amino acid, a hydrophobic moiety, an aromatic amino acid, alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, methionine, tyrosine, arginine, histidine, lysine, glycine, serine, threonine, cysteine, tyrosine, asparagine, aspartic acid, glutamic acid, and glutamine and derivatives thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein X is a length from 7 atoms to 14 atoms.

### Claim 4 (depends on 1)

The method of claim 1, wherein X is selected from the group consisting of: six aminohectanoic acid (SAHA), eight aminooctonoic acid (EAOA), polyethylene glycol (PEG), polyethylene amine (PEA) unit, a chain or spacer of 6 atoms, a chain or spacer from 6 to 20 atoms in length, a peptide compromising positively charged amino acids or quaternary amine containing amino acid, and a peptide comprising aryl or aryl alkyl groups, each of which is optionally substituted, and wherein one aryl or aryl alkyl group is about 6 to about 10, or about 6 to about 14 atoms, and the other aryl or aryl alkyl group is about 10 to about 14, or about 10 to about 15 atoms, or about 1 to about 20 atoms.

### Claim 5 (depends on 1)

The method of claim 1, wherein Y is selected from the group consisting of an amino acid spacer with a chalcogen-containing side chain group, an amino acid spacer with a sulfur-containing side chain group, an amino acid spacer with a sulfur-containing thiophenol moiety, a tyrosine with a carbon isotope on the aromatic ring of tyrosine, an amino acid with an aromatic ring with a hydrogen isotope, aspartic acid, glutamic acid, arginine, histidine, lysine, glycine, serine, threonine, cysteine, tyrosine, asparagine, aspartic acid, glutamic acid, glutamine, alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, methionine, and derivatives thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein Z is selected from the group consisting of IR800, SP054, S0121, KODAK, S2076, S0456,
wherein R41, R42, R43, R44, R45, R46, R47, R48, ═H or SO3H; X=CH2, O, S, or NH.

### Claim 7 (depends on 1)

The method claim 1, wherein B is
wherein n is 0, m is 5 and p is 2;
W is selected from the group consisting of EAOA, PEG, and PEA;
X is selected from the group consisting of EAOA, PEG, and PEA;
Y is selected from the group consisting of tyrosine, phenylalanine-tyrosine, phenylalanine-arginine-tyrosine, and histidine-tyrosine;
and Z comprises S0456.

### Claim 8 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of:

### Claim 9 (depends on 1)

The method of claim 1, wherein the diagnostic imaging is fluorescence-guided surgery or image-guided surgery.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier, excipient, or diluent.

### Claim 11 (depends on 1)

The method of claim 1, wherein the method further comprises the steps of:
contacting the diseased tissue with the composition;
allowing time for the compound to distribute within the diseased tissue; and
illuminating the diseased tissue with an excitation light of a wavelength absorbable by the compound.

### Claim 12 (depends on 11)

The method of claim 11, further comprising the step of detecting the optical signal emitted by the compound.

### Claim 13 (depends on 12)

The method of claim 12, further comprising the step of diagnosing the subject with a disease associated with pathogenic populations of cells expressing or over expressing CA-IX.

### Claim 14 (depends on 11)

The method of claim 11, further comprising the step of performing surgical resection of the diseased tissue.

### Claim 15 (depends on 11)

The method of claim 11, wherein the excitation wavelength is in the near infrared range.

### Claim 16 (depends on 11)

The method of claim 11, wherein the excitation wavelength is from about 600 nm to about 1000 nm.

### Claim 17 (depends on 1)

The method of claim 1, wherein the diseased tissue is selected from the group consisting of cancer cells, tumor tissue, inflammatory cell, inflamed tissue, infected cell, and infected tissue.

### Claim 18 (depends on 17)

The method of claim 17, wherein the diseased tissue is a cancer cell selected from the group consisting of bladder cancer cells, pancreatic cancer cells, liver cancer cells, lung cancer cells, kidney cancer cells, sarcoma cells, breast cancer cells, brain cancer cells, neuroendocrine carcinoma cells, colon cancer cells, prostate cancer cells, testicular cancer cells, and melanoma cells.

### Claim 19 (depends on 17)

The method of claim 17, wherein the diseased tissue is an inflammatory cell, wherein the inflammatory cell is from an inflammatory disease selected from the group consisting of: ulcerative colitis, rheumatoid arthritis, Juvenile idiopathic arthritis (JIA), pulmonary fibrosis, atherosclerosis, multiple sclerosis, lupus erythematosus, psoriasis, osteomyelitis, Crohn's disease, graft versus host disease (GVHD), fibromyalgia, osteoarthritis, sarcoidosis, systemic sclerosis, Sjogren's syndrome, inflammations of the skin (e.g., psoriasis), glomerulonephritis, proliferative retinopathy, restenosis, and chronic inflammations.

### Claim 20 (depends on 1)

The method of claim 1, wherein the subject is a human or animal.
